Metachronous colorectal cancer metastasis: Who, what, when and what to do about it

被引：4
|
作者：
Cohen, Ryan [1 ,2 ,4 ]
Platell, Cameron F. [2 ,3 ]
机构：
[1] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia
[2] St John God Subiaco Hosp, Colorectal Canc Unit, Perth, WA, Australia
[3] Univ Western Australia, Sch Med, Perth, WA, Australia
[4] Room 242 M Block QEII Med Ctr,6 Verdun St, Perth, WA 6009, Australia
来源：
JOURNAL OF SURGICAL ONCOLOGY | 2024年 / 129卷 / 01期
关键词：
colorectal neoplasms; delayed metastasis; metachronous metastasis; neoplasm metastasis; CIRCULATING-TUMOR DNA; EPITHELIAL-MESENCHYMAL TRANSITIONS; CARCINOEMBRYONIC ANTIGEN CEA; MINIMAL RESIDUAL DISEASE; FOLLOW-UP; LIVER METASTASES; CLINICOPATHOLOGICAL FEATURES; POSTOPERATIVE SURVEILLANCE; HEPATIC METASTASES; RECTAL-CANCER;
D O I：
10.1002/jso.27400
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metachronous colorectal cancer (CRC) metastasis occurs due to micrometastatic disease, in up to 23% of patients who have undergone curative-intent treatment. Metachronous metastasis tends to occur within 2 years of initial treatment. Diagnosis relies on posttreatment surveillance strategies. Care for patients with metachronous CRC metastasis is complex and requires careful multidisciplinary consideration. Those with isolated and technically resectable diseases are recommended to undergo metastasectomy with adjunct chemotherapy, however, survival, even after curative-intent resection, is poor.
引用
收藏
页码：71 / 77
页数：7
相关论文
共 50 条
12345